John Stoltzfus, chief investment strategist at Oppenheimer, says the firm's 7,100 year-end target for the S&P 500 is "under ...

The early reactions to Ryan Coogler's Sinners are out, and people are raving about the director's bold and audacious vision.

Key Takeaways Oppenheimer analysts on Thursday said that given this week's tariff news, they prefer defensive consumer stocks ...

The action "jolts forward" when an outsider (Moses Ingram) somehow enters the bunker, said Danny Leigh in the Financial Times ...

Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative ...

Despite recent market turbulence, Oppenheimer Asset Management expressed continued optimism about equities. Learn more here.

Christopher Nolan’s Oppenheimer was that rare movie that was both a box office hit and a serious award winner. It also had ...

The director of ‘The End’ discusses getting tips from Werner Herzog and how contemplating catastrophe can make us more human ...

As interest rates fall, business development companies', or BDCs, return on equity will likely be pressured. Oppenheimer ...

Oppenheimer Asset Management Inc. reduced its position in shares of NVIDIA Co. (NASDAQ:NVDA – Free Report) by 2.1% during the ...

Oppenheimer raised the firm’s price target on AT&T to $32 from $27 and keeps an Outperform rating on the shares. The firm cites better free ...

In a report released today, Matthew Biegler from Oppenheimer reiterated a Buy rating on Biomea Fusion (BMEA – Research Report), with a price ...